SCHEMBL19914916

SCHEMBL19914916

Cc1ccc(CCNC(=O)C(F)(F)F)cc1I

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
MTNR1A P48039 4/20 0.40
MTNR1B P49286 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
PTGS1 P23219 1/20 0.40
BLM P54132 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NQO2 P16083 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALPL P05186 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7641978 0.80 CNR1 (0.41) CNR1MTNR1AMTNR1BALDH1A1KDM4E
SCHEMBL4702861 0.79 ALDH1A1 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2MEN1
SCHEMBL14141265 0.79 NPC1 (0.59) CNR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL10593239 0.76 MAPT (0.64) ALDH1A1KDM4ELMNAMAPTHPGD
SCHEMBL3769977 0.76 CA1 (0.47) MEN1KMT2A
SCHEMBL184041 0.75 TRPV1 (0.59) CNR1LMNAMAPTMEN1KMT2A
SCHEMBL1968355 0.74 CA12 (0.66) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL9128943 0.74 MTNR1A (0.53) MTNR1AMTNR1BALDH1A1KDM4EMAPT
SCHEMBL5148312 0.74 TRPV1 (0.48) ALDH1A1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL6433557 0.73 KDM4E (0.61) ALDH1A1KDM4EMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2374796-B1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes ARENA PHARM INC (US) 2018-02-28 EP disclosed